Showing results (111-120 of 177) with videos related to

Sort By:
Pageof 18
Oncoimmunology|June 7, 2018
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2Na Luo, Luigi Formisano, Paula I Gonzalez-Ericsson, et al.
Cancers|July 25, 2019
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature ReviewFabiana Napolitano, Luigi Formisano, Alessandro Giardino, et al.
Critical Reviews in Oncology/Hematology|September 20, 2025
Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research studyAnnarita Avanzo, Fabio Salomone, Massimo Di Maio, et al.
Physiologia Plantarum|May 22, 2024
Unravelling the biostimulant activity of a protein hydrolysate in lettuce plants under optimal and low N availability: a multi-omics approachSonia Monterisi, Pascual Garcia-Perez, Valentina Buffagni, et al.
Breast Cancer Research : BCR|June 3, 2014
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer modelsLuigi Formisano, Lucia Nappi, Roberta Rosa, et al.
Cancers|October 13, 2021
Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational StudyAlberto Servetto, Antonio Santaniello, Fabiana Napolitano, et al.
Journal of the National Cancer Institute|August 26, 2025
Censoring in trials testing immunotherapy in advanced cancers. A systematic review and a meta-research studyFilippo Vitale, Fabio Salomone, Massimo Di Maio, et al.
Expert Opinion on Drug Safety|March 22, 2021
How can we manage the cardiac toxicity of immune checkpoint inhibitors?Remo Poto, Giancarlo Marone, Flora Pirozzi, et al.
ESMO Open|September 22, 2020
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 eraGrazia Arpino, Carmine De Angelis, Pietro De Placido, et al.
International Journal of Cancer|February 8, 2023
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian InstitutionsVincenzo De Falco, Gabriella Suarato, Rossella Napolitano, et al.
Pageof 18